Evidence map›Paper›PMID 29530037›Full record

ArticleBMC veterinary research2018

Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.

Xóchitl Zambrano-Estrada, Brianda Landaverde-Quiroz, Andrés A Dueñas-Bocanegra, Marco A De Paz-Campos, Gerardo Hernández-Alberto, Benjamín Solorio-Perusquia, Manuel Trejo-Mandujano, Laura Pérez-Guerrero, Evangelina Delgado-González, Brenda Anguiano and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03688958 (Effect of Dietary Iodine Supplementation on the Proliferation of Breast Cancer), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03688958 phase2unknown statusnot on this map

Effect of Dietary Iodine Supplementation on the Proliferation of Breast Cancer

TypeinterventionalSponsorUniversidad Nacional Autonoma de MexicoRan2005 to 2020Enrolled120ConditionsBreast CancerArmsPlacebo, iodine, FEC/TE Placebo, FEC/TE iodine
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Metabolic Alterations in Canine Mammary Tumors.Animals : an open access journal from MDPI · 2023
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xóchitl Zambrano-EstradaInstituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, CP 76230, Querétaro, Mexico.
Brianda Landaverde-QuirozFacultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Andrés A Dueñas-BocanegraFacultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Marco A De Paz-CamposFacultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Gerardo Hernández-AlbertoFacultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Benjamín Solorio-PerusquiaFacultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Mexico City, Mexico.
Manuel Trejo-MandujanoFacultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Mexico City, Mexico.
Laura Pérez-GuerreroFacultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Mexico City, Mexico.
Evangelina Delgado-GonzálezInstituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, CP 76230, Querétaro, Mexico.
Brenda AnguianoInstituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, CP 76230, Querétaro, Mexico.
Carmen AcevesInstituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, CP 76230, Querétaro, Mexico. caracev@unam.mx.ORCID http://orcid.org/0000-0001-9418-8304
Universidad Nacional Autónoma de México · MXAutonomous University of Queretaro · MX

Funding

CONACYT 235961CONACYT 356685PAPIIT-UNAM 200813PAPIIT-UNAM 201516PAPIIT-UNAM 209717
6 · The paper itself

Abstract

backgroundMammary cancer has a high incidence in canines and is an excellent model of spontaneous carcinogenesis. Molecular iodine (I

resultsmDOX attenuated the severity of adverse events (VCOG-CTCAE) in comparison with the sDOX group. The overall tumor response rate (RECIST criteria) for all dogs was 18% (interval of reduction 48-125%), and no significant difference was found between groups. I

conclusionsThe mDOX+I

Indexed as

AnimalsAntineoplastic AgentsDog DiseasesDogsDoxorubicinFemaleIodineMammary Neoplasms, AnimalNeoadjuvant TherapyAntineoplastic AgentsDoxorubicinIodineAnimal welfareCanine mammary cancerDoxorubicinMolecular iodineNeoadjuvant chemotherapy

Identifiers

PMID29530037
PMCPMC5848438
OpenAlexW2805909842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.